Abstract
Objective: Folate receptor alpha (FolRa) is a cell-surface glycoprotein, highly expressed in ovarian and endometrial adenocarcinoma, and is thus a promising target for cancer therapy using antibody drug conjugates (ADCs). We have employed an E. coli cell-free expression system (XpressCFTM) and site-specific conjugation technology to generate STRO-002, a novel, site-specific, and homogenous FolRa-targeting ADC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
